Hopewell Therapeutics Announces Sublicense of Proprietary Lipid Nanoparticles for Novel Cancer Vaccine to Foxcroft TherapeuticsWOBURN, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Hopewell Therapeutics, Inc., a Boston-based next-generation lipid nanoparticle (LNP) company (“Hopewell”), today announced that it entered into a sublicense agreement with Foxcroft Therapeutics, Inc., the developer of novel cancer vaccines (“Foxcroft”), granting Foxcroft a global sublicense to certain of its tissue-targeting LNPs (ttLNPs). Hopewell and Foxcroft will collaborate on their evaluation of Hopewell’s ttLNPs as potential delivery vehicles for Foxcroft’s cancer vaccines.
